What is the ROE (Return on Equity) of Bio-Techne this year?
The ROE of Bio-Techne this year is 0.15 undefined.
Bio-Techne ROE 2024
Bio-Techne ROE
0.15
Bio-Techne Dividend yield
0.89 %
Ticker
TECH
ISIN
US09073M1045
WKN
A12ENG
In 2024, Bio-Techne's return on equity (ROE) was 0.15, a -9.23% increase from the 0.16 ROE in the previous year.
Bio-Techne Aktienanalyse
What does Bio-Techne do?
Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently. Bio-Techne ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Bio-Techne's Return on Equity (ROE)
Bio-Techne's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Bio-Techne's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Bio-Techne's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Bio-Techne’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Bio-Techne Stock
How has the Return on Equity (ROE) of Bio-Techne developed compared to the previous year?
The ROE of Bio-Techne has increased by -9.23% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Bio-Techne?
A high ROE indicates that Bio-Techne generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Bio-Techne?
A low ROE can indicate that Bio-Techne is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Bio-Techne affect the company?
A change in ROE (Return on Equity) of Bio-Techne can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Bio-Techne?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Bio-Techne?
Some factors that can influence Bio-Techne's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Bio-Techne pay?
Over the past 12 months, Bio-Techne paid a dividend of 0.56 USD . This corresponds to a dividend yield of about 0.89 %. For the coming 12 months, Bio-Techne is expected to pay a dividend of 0.56 USD.
What is the dividend yield of Bio-Techne?
The current dividend yield of Bio-Techne is 0.89 %.
When does Bio-Techne pay dividends?
Bio-Techne pays a quarterly dividend. This is distributed in the months of September, December, December, March.
How secure is the dividend of Bio-Techne?
Bio-Techne paid dividends every year for the past 0 years.
What is the dividend of Bio-Techne?
For the upcoming 12 months, dividends amounting to 0.56 USD are expected. This corresponds to a dividend yield of 0.89 %.
In which sector is Bio-Techne located?
Bio-Techne is assigned to the 'Health' sector.
Wann musste ich die Aktien von Bio-Techne kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Bio-Techne from 2/26/2024 amounting to 0.08 USD, you needed to have the stock in your portfolio before the ex-date on 2/9/2024.
When did Bio-Techne pay the last dividend?
The last dividend was paid out on 2/26/2024.
What was the dividend of Bio-Techne in the year 2023?
In the year 2023, Bio-Techne distributed 1.043 USD as dividends.
In which currency does Bio-Techne pay out the dividend?
The dividends of Bio-Techne are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Bio-Techne
Our stock analysis for Bio-Techne Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bio-Techne Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
